Cleemann L, Holm K, Fallentin E, et al. - In this double-blind, 5-year randomized controlled clinical trial involving 20 young Turner syndrome (TS) women (19.2 ± 2.5 years, range 16.0–24.9), researchers contrasted two doses of oral 17ß-estradiol on uterine size. The research was performed by 16 patients. The lower dose (LD) group took 2 mg 17ß-estradiol/d orally and placebo, on the other hand, the higher dose (HD) group took 4 mg 17ß-estradiol/d orally. Within the first years of treatment, HD oral 17ß-estradiol causes a steeper rise in uterine volume compared with LD. However, in most young TS women, the uterine growth potential seems to be the same, making the duration of treatment as important as the dose of estrogen, although a few TS women did not experience enough uterine growth on 2 mg of estradiol.